Show simple item record

dc.contributor.authorTayao, M
dc.contributor.authorAndrici, J
dc.contributor.authorFarzin, M
dc.contributor.authorClarkson, A
dc.contributor.authorSioson, L
dc.contributor.authorWatson, N
dc.contributor.authorChua, TC
dc.contributor.authorSztynda, T
dc.contributor.authorSamra, JS
dc.contributor.authorGill, AJ
dc.date.accessioned2019-10-16T05:33:00Z
dc.date.available2019-10-16T05:33:00Z
dc.date.issued2016
dc.identifier.issn1932-6203
dc.identifier.doi10.1371/journal.pone.0150338
dc.identifier.urihttp://hdl.handle.net/10072/388435
dc.description.abstractBACKGROUND: Pancreatic cancer is both common and highly lethal and therefore new biomarkers or potential targets for treatment are needed. Loss of BRCA associated protein-1 (BAP1) expression has been found in up to a quarter of intrahepatic cholangiocarcinomas. Given the close anatomical relationship between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma, we therefore sought to investigate the frequency of loss of BAP1 expression in pancreatic ductal adenocarcinoma. METHODS: The records of the department of Anatomical Pathology Royal North Shore Hospital, Sydney, Australia, were searched for cases of pancreatic ductal adenocarcinoma diagnosed between 1992 and 2014 with material available in archived formalin fixed paraffin embedded tissue blocks. Immunohistochemistry for BAP1 was performed on tissue microarray sections and if staining was equivocal or negative it was confirmed on whole sections. Negative staining for BAP1 was defined as loss of expression in all neoplastic nuclei, with preserved expression in non-neoplastic cells which acted as an internal positive control. RESULTS: Loss of BAP1 expression was found in only 1 of 306 (0.33%) pancreatic ductal adenocarcinomas. This case was confirmed to demonstrate diffuse loss of expression throughout all neoplastic cells in multiple blocks, consistent with BAP1 loss being an early clonal event. All other cases demonstrated positive expression of BAP1. CONCLUSION: We conclude that, in contrast to intrahepatic cholangiocarcinoma, loss of expression of BAP1 occurs very rarely in pancreatic ductal adenocarcinoma. Therefore BAP1 inactivation is unlikely to be a frequent driver abnormality in pancreatic adenocarcinoma.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherPublic Library of Science
dc.publisher.placeUnited States
dc.relation.ispartofpagefrome0150338: 1
dc.relation.ispartofpagetoe0150338: 11
dc.relation.ispartofissue3
dc.relation.ispartofjournalPloS one
dc.relation.ispartofvolume11
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchcode1112
dc.titleLoss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationTayao, M; Andrici, J; Farzin, M; Clarkson, A; Sioson, L; Watson, N; Chua, TC; Sztynda, T; Samra, JS; Gill, AJ, Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma, PloS one, 2016, 11 (3), pp. e0150338: 1-e0150338: 11
dcterms.dateAccepted2016-02-12
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.date.updated2019-10-16T01:38:13Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2016 Tayao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
gro.hasfulltextFull Text
gro.griffith.authorChua, Terence


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record